Did you mean 9005 39 8?
Displaying drugs 51 - 75 of 1906 in total
Fluconazole
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole...
Approved
Investigational
Matched Mixtures name: … Ciclopirox 8% / Fluconazole 1% / Terbinafine HCl 1% …
Matched Products: … FLUCAN 150 MG KAPSUL, 8 ADET ... FLUZAMED 150 MG KAPSÜL ,8 KAPSÜL …
Matched Products: … FLUCAN 150 MG KAPSUL, 8 ADET ... FLUZAMED 150 MG KAPSÜL ,8 KAPSÜL …
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Iupac: … 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin …
Matched Salts cas: … 753498-25-8 …
Matched Salts cas: … 753498-25-8 …
Etanercept
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1....
Approved
Investigational
Matched Products: … ENBREL 25 MG/0,5 ML SC ENJEKSIYONLUK COZELTI İÇİN KULLANIMA HAZIR ENJEKTÖR, 8 ADET …
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Methocarbamol
Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether. Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of...
Approved
Vet approved
Matched Mixtures name: … Spasmhalt-8 ... Axacet-C1/8 ... Axisal-C1/8 …
Dioxybenzone
Dioxybenzone, or benzophenone-8, is an organic compound derived from DB01878 that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays. Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% .
Approved
Matched Description: … Dioxybenzone, or benzophenone-8, is an organic compound derived from [DB01878] that is used as a sunscreen …
Krypton Kr 81m
Approved
Methionine
A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Approved
Nutraceutical
Matched Mixtures name: … AMINOSTERIL N-HEPA 8% ... HEPATAMINE %8 500 ML(SETLI) ... HEPATAMINE %8 500 ML(SETSIZ) …
Pamidronic acid
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming...
Approved
Matched Description: … [A203111]
Pamidronic acid was granted FDA approval on 31 October 1991.[L13835] …
Deferasirox
Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Approved
Investigational
Acer saccharum pollen
Acer saccharum pollen is the pollen of the Acer saccharum plant. Acer saccharum pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Eastern 8 Tree Pollen Mix ... Eastern 8 Tree Pollen Mix ... Eastern 8 Tree Pollen Mix …
Elranatamab
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Matched Description: … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437] …
Gilteritinib
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Simeprevir
Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United...
Approved
Matched Iupac: … (1R,4R,6R,7Z,15R,17R)-N-(cyclopropanesulfonyl)-17-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol …
Repaglinide
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood...
Approved
Investigational
Matched Description: … Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine. ... have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8- …
Flurbiprofen
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis....
Approved
Investigational
Matched Mixtures name: … MULTIFLEX 200/8 MG SR KAPSUL, 14 ADET ... FULDUO 100 MG/8 MG FİLM KAPLI TABLET, 14 ADET …
Dapsone
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of...
Approved
Investigational
Matched Description: … (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) …
Ecamsule
Ecamsule is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability. Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only...
Approved
Matched Mixtures name: … Lait Protecteur SPF 8 ... Soin Solaire SPF 8-crm ... Lait Bronzant Hydro-nutritif SPF 8 …
Zinc sulfate, unspecified form
Zinc sulfate is a common zinc supplement in parenteral nutrition.[A216916,L12888]
Approved
Experimental
Matched Mixtures name: … Equate 8-symptom Relief ... Life Brand 8 Symptom Relief ... Personnelle 8 Symptom Relief …
Nifedipine
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine.[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer...
Approved
Matched Description: … [A190273]
Nifedipine was granted FDA approval on 31 December 1981.[L11383] …
Patent Blue
Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Description: … Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979. …
Motixafortide
Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's...
Approved
Investigational
Acrivastine
Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia.
Acrivastine is...
Approved
Matched Mixtures name: … DUACT 8 MG/60 MG KAPSÜL, 30 ADET …
Amoxapine
Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation....
Approved
Luspatercept
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Displaying drugs 51 - 75 of 1906 in total